Table 3.
Comparison of clinical parameters of T2DM patients with eGFR ≥ and eGFR <60 mL/min between VF(+) and VF(−) groups of patients (n = 173)
| eGFR ≥60 (mL/min/1.73 m2) | eGFR <60 (mL/min/1.73 m2) | |||||
|---|---|---|---|---|---|---|
| VF(+) (n = 17) | VF(−) (n = 88) | p value | VF(+) (n = 22) | VF(−) (n = 46) | p value | |
| eGFR (mL/min/1.73 m2) | 71.0 ± 8.5 | 81.9 ± 15.7 | 0.010* | 41.9 ± 16.6 | 38.2 ± 14.7 | 0.245 |
| Age (year) | 65.5 ± 12.1 | 58.0 ± 12.2 | 0.035* | 71.0 ± 6.6 | 65.5 ± 10.8 | 0.025* |
| Gender (men/women) | 9/8 | 45/43 | 0.891 | 11/11 | 33/13 | 0.079 |
| Duration of T2DM (year) | 21.0 (16.7–25.3) | 8.0 (1.5–14.5) | <0.001* | 18.0 (8.5–27.5) | 15.0 (7.0–23.0) | 0.573 |
| HbA1c (%) | 8.1 ± 1.6 | 8.5 ± 1.7 | 0.247 | 7.4 ± 1.5 | 8.0 ± 1.5 | 0.134 |
| Ca (mg/dL) | 9.3 ± 0.4 | 9.2 ± 0.4 | 0.362 | 9.0 ± 0.8 | 9.2 ± 0.6 | 0.182 |
| Phosphate (mg/dL) | 3.9 (3.6–4. 2) | 3.9 (3.5–4.3) | 0.766 | 3.8 (3.5–4.1) | 3.7 (3.3–4.1) | 0.318 |
| BAP (μg/L) | 14.6 (11.0–18.2) | 12.5 (8.7–16.3) | 0.322 | 16.0 (12.1–19.9) | 12.0 (8.2–15.8) | 0.015* |
| Intact OC (ng/mL) | 3.0 (0.6–5.4) | 2.8 (1.8–3.8) | 0.350 | 5.3 (3.7–6.9) | 3.5 (1.8–5.2) | 0.070 |
| 1,25(OH)2D (pg/mL) | 42.0 (33.2–50.8) | 46.0 (33.4–58.6) | 0.569 | 28.0 (39.5–36.5) | 29.0 (18.5–39.5) | 0.700 |
| Whole PTH (pg/mL) | 17.7 (12.8–22.6) | 17.2 (13.1–21.3) | 0.647 | 24.9 (15.1–34.7) | 23.7 (14.8–32.6) | 0.064 |
| TRACP-5b (mU/dL) | 396 (238–554) | 325 (228–422) | 0.165 | 456 (367–545) | 361 (223–499) | 0.196 |
| TrBMD (mg/cm3) | 155 ± 55 | 177 ± 52 | 0.134 | 129 ± 36 | 188 ± 56 | <0.001* |
| EMTb (Gpa) | 2.66 (2.46–2.86) | 3.05 (2.77–3.33) | 0.007* | 2.72 (2.56–2.88) | 3.07 (2.78–3.36) | 0.004* |
| CoTh (mm) | 3.07 ± 1.16 | 3.71 ± 1.21 | 0.060 | 2.86 ± 1.10 | 4.19 ± 1.32 | 0.001* |
Data are expressed as mean ± SD and were analyzed by Student’s t test or median (IQR) and were analyzed by Mann-Whitney U test. χ 2 tests were used to analyze the differences between men and women
*p < 0.05 (statistical significance)